Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Caribou Biosciences, Inc.

< Previous 1 2 Next >
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Proposed Public Offering of Common Stock
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU PFE
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
From Caribou Biosciences, Inc.
Via Business Wire
Tickers CRBU
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
From Caribou Biosciences, Inc.
Via Business Wire
Tickers CRBU
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
From Caribou Biosciences, Inc.
Via Business Wire
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
From Caribou Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback